Parabilis' Helicon Platform Evolves: Targeting Protein Degraders, RIPTACs & Radiopharmaceuticals

Parabilis has outlined its progress in advancing its proprietary Helicon platform from proof-of-concept (POC) to exploring new therapeutic indications and tackling complex drug targets. The company is now investigating the potential of Helicons in three key areas: protein degraders, RIPTACs (Regulated Intracellular Proteolysis Targeting Chimeras), and radiopharmaceuticals. CEO Mathai Mammen discussed these developments, emphasizing the scientific foundation driving these efforts. The Helicon platform, according to Mammen, demonstrates versatility that enables it to address challenging biological mechanisms. Parabilis aims to leverage this technology to expand into emerging fields such as targeted protein degradation and radiopharmaceutical therapies, which are gaining traction for their precision in treating diseases. Additionally, the company is exploring RIPTACs, a novel approach designed to regulate intracellular proteolysis with high specificity. These advancements reflect Parabilis’ strategy to broaden its scope beyond initial POC studies and apply its platform across diverse therapeutic landscapes. Newsflash | Powered by GeneOnline AI Source: GO-AI-ne1 For any suggestion and feedback, please contact us. Date: January 20, 2026